Skip to main navigation Skip to search Skip to main content

Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry

  • the ESC-EORP-HFA Heart Failure Long-Term Registry Investigators
  • Carol Davila University of Medicine and Pharmacy
  • Université Paris Cité
  • Associazione Nazionale Medici Cardiologi Ospedalieri
  • European Society of Cardiology
  • University of Helsinki
  • St George's University Hospitals NHS Foundation Trust
  • IRCCS San Raffaele Pisana - Roma
  • Guglielmo da Saliceto Hospital
  • Centro de Investigación Biomédica en Red
  • General Hospital Murska Sobota
  • Wrocław Medical University
  • Wrocław Military Hospital
  • National and Kapodistrian University of Athens
  • University of Cyprus
  • University of Zurich
  • University of Belgrade
  • Karolinska Institutet

Research output: Contribution to journalArticlepeer-review

312 Scopus citations

Abstract

Aims: Classification of acute heart failure (AHF) patients into four clinical profiles defined by evidence of congestion and perfusion is advocated by the 2016 European Society of Cardiology (ESC)guidelines. Based on the ESC-EORP-HFA Heart Failure Long-Term Registry, we compared differences in baseline characteristics, in-hospital management and outcomes among congestion/perfusion profiles using this classification. Methods and results: We included 7865 AHF patients classified at admission as: ‘dry-warm’ (9.9%), ‘wet-warm’ (69.9%), ‘wet-cold’ (19.8%) and ‘dry-cold’ (0.4%). These groups differed significantly in terms of baseline characteristics, in-hospital management and outcomes. In-hospital mortality was 2.0% in ‘dry-warm’, 3.8% in ‘wet-warm’, 9.1% in ‘dry-cold’ and 12.1% in ‘wet-cold’ patients. Based on clinical classification at admission, the adjusted hazard ratios (95% confidence interval) for 1-year mortality were: ‘wet-warm’ vs. ‘dry-warm’ 1.78 (1.43–2.21) and ‘wet-cold’ vs. ‘wet-warm’ 1.33 (1.19–1.48). For profiles resulting from discharge classification, the adjusted hazard ratios (95% confidence interval) for 1-year mortality were: ‘wet-warm’ vs. ‘dry-warm’ 1.46 (1.31–1.63) and ‘wet-cold’ vs. ‘wet-warm’ 2.20 (1.89–2.56). Among patients discharged alive, 30.9% had residual congestion, and these patients had higher 1-year mortality compared to patients discharged without congestion (28.0 vs. 18.5%). Tricuspid regurgitation, diabetes, anaemia and high New York Heart Association class were independently associated with higher risk of congestion at discharge, while beta-blockers at admission, de novo heart failure, or any cardiovascular procedure during hospitalization were associated with lower risk of residual congestion. Conclusion: Classification based on congestion/perfusion status provides clinically relevant information at hospital admission and discharge. A better understanding of the clinical course of the two entities could play an important role towards the implementation of targeted strategies that may improve outcomes.

Original languageEnglish
Pages (from-to)1338-1352
Number of pages15
JournalEuropean Journal of Heart Failure
Volume21
Issue number11
DOIs
StatePublished - 1 Nov 2019

Bibliographical note

Publisher Copyright:
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology

Funding

Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2016), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), Servier (2009–2021), Vifor (2019–2022).

FundersFunder number
Gedeon Richter Plc.
MSD-Merck & Co.
Menarini Int
Pfizer Alliance
Fogarty International CenterF06TW002012
Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
Bayer
Novartis
Boehringer Ingelheim
Boston Scientific Corporation
Daiichi Sankyo Europe

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Acute heart failure
    • Congestion
    • Forrester classification
    • Outcomes
    • Perfusion
    • Registry

    Fingerprint

    Dive into the research topics of 'Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry'. Together they form a unique fingerprint.

    Cite this